2m 2m 2m 2m 2m 2m 2m
ORIC PHARMA (ORIC)
NASDAQ
$9.02+$0.09 (+0.95%)
Price as of Jun 23, 2026 3:14 PM EDT- $924.4MMarket Cap
- -10.70%1-Year Change
- BiotechnologyIndustry
ORIC PHARMA (ORIC)
$9.02+$0.09 (+0.95%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -109.8M -3.73% | -114.1M +33.93% | -85.2M +27.73% | -66.7M +17.27% | |
Depreciation and Amortization Expense | 1.2M +10.21% | 1.1M +7.27% | 1.0M +6.83% | 966,000 +7.69% | |
Total Operating Expenses | 143.0M +0.08% | 142.9M +28.99% | 110.8M +20.72% | 91.8M +16.35% | |
Operating Profit | -143.0M +0.08% | -142.9M +28.99% | -110.8M +20.72% | -91.8M +16.35% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 -100.00% | |
Total Nonoperating Income and Expense | 13.5M -10.05% | 15.0M +49.24% | 10.1M +281.21% | 2.6M +1,595.51% | |
Income before Taxes | -143.0M +0.08% | -142.9M +28.99% | -110.8M +20.72% | -91.8M +16.35% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -129.5M +1.27% | -127.8M +26.96% | -100.7M +12.99% | -89.1M +13.22% | |
Net Income from Continuing Operations Applicable to Common | -129.5M +1.27% | -127.8M +26.96% | -100.7M +12.99% | -89.1M +13.22% | |
Basic EPS and Net Income | -1.47 -19.67% | -1.83 -6.63% | -1.96 -12.89% | -2.25 +8.70% | |
Diluted EPS and Net Income | -1.47 -19.67% | -1.83 -6.63% | -1.96 -12.89% | -2.25 +8.70% | |
Basic Weighted Average Shares | 87.8M +25.91% | 69.7M +35.52% | 51.5M +29.75% | 39.7M +4.48% | |
Diluted Weighted Average Shares | 87.8M +25.91% | 69.7M +35.52% | 51.5M +29.75% | 39.7M +4.48% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 45.7M -23.12% | 59.4M +154.05% | 23.4M -65.01% | 66.8M -70.43% | |
Short-Term Investments | 235.8M +19.98% | 196.6M +6.36% | 184.8M +32.54% | 139.4M +1,170.68% | |
Cash and Cash Equivalents and Short-Term Investments | 281.5M +9.97% | 256.0M +22.95% | 208.2M +0.93% | 206.3M -12.96% | |
Total Current Assets | 288.5M +10.00% | 262.3M +23.36% | 212.6M +1.02% | 210.5M -12.50% | |
Accumulated Depreciation | 7.7M +2.34% | 7.5M +15.12% | 6.5M +12.10% | 5.8M +16.12% | |
Property and Plant and Equipment and Net | 2.4M -17.41% | 2.9M +2.17% | 2.9M -12.02% | 3.3M +34.81% | |
Total Long-Term Assets | 7.2M -19.19% | 9.0M -7.51% | 9.7M -15.81% | 11.5M -6.53% | |
Total Assets | 408.9M +49.15% | 274.1M +8.78% | 252.0M +1.95% | 247.2M -17.23% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 20.4M -17.83% | 24.8M +21.45% | 20.5M +32.95% | 15.4M +1.56% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 4.1M -33.41% | 6.2M -17.25% | 7.5M -20.96% | 9.4M -10.23% | |
Total Liabilities | 24.5M -20.93% | 31.0M +11.11% | 27.9M +12.45% | 24.8M -3.27% | |
Retained Earnings | -692.2M +23.01% | -562.8M +29.40% | -434.9M +30.13% | -334.2M +36.36% | |
Total Stockholders Equity | 384.4M +58.09% | 243.1M +8.49% | 224.1M +0.78% | 222.4M -18.55% | |
Total Shares Outstanding | 98.5M +38.73% | 71.0M +29.45% | 54.9M +21.68% | 45.1M +14.35% | |
Cash Flow | |||||
Cash from Operating Activities | -111.0M -1.50% | -112.7M +31.48% | -85.7M +14.03% | -75.1M +26.20% | |
Capital Expenditures | 712,000 -40.07% | 1.2M +39.93% | 849,000 -59.14% | 2.1M +121.30% | |
Cash from Investing Activities | -148.0M -768.70% | 22.1M +151.00% | -43.4M -60.27% | -109.2M -168.95% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 245.3M +93.81% | 126.5M +47.74% | 85.7M +239.58% | 25.2M -48.66% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -37.91% -21.99% | -48.60% +20.46% | -40.34% +23.54% | -32.66% +23.97% | |
Return on Equity | -41.27% -24.60% | -54.73% +21.32% | -45.11% +25.36% | -35.99% +28.63% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 14.13 +33.86% | 10.56 +1.57% | 10.39 -24.02% | 13.68 -13.85% | |
Cash Ratio | 2.24 -6.45% | 2.39 +109.19% | 1.14 -73.69% | 4.34 -70.88% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow